GLP1s Update: Ozempic and Wegovy Shortages Resolved by F.D.A.
GLP1s Update on Ozempic and Wegovy
The F.D.A. has officially announced that shortages of Ozempic and Wegovy, both glucagon-like peptide-1 (GLP-1) receptor agonists, have come to an end. This significant development will enhance patient access to essential prescription drugs aimed at managing diabetes and assisting with weight loss.
Impact on Compounded Pharmaceuticals
While the lifting of shortages is positive for patients, it introduces challenges for the future of compounded versions of these medications. As demand stabilizes, health care providers and pharmacies must adapt to changes in the pharmaceutical landscape.
- Patient access to GLP1s improved
- Pharmacy adjustments required
- Future of compounded medications uncertain
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.